Form 4 for SYRE Spyre Therapeutics, Inc.
Accepted 2023-11-27 00:00:00 ET · period of report 2023-11-22 · accession 0000950170-23-066131 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-11-27 | 2023-11-24 | SYRE | Turtle Cameron | CEO, Dir | C - Cnv Deriv | $0.00 | +723.4K | 746.5K | +3,136% | $0 |
| D | 2023-11-27 | 2023-11-24 | SYRE | Turtle Cameron | CEO, Dir | C - Cnv Deriv | $0.00 | -18.1K | 0 | -100% | $0 |
| D | 2023-11-27 | 2023-11-22 | SYRE | Turtle Cameron | CEO, Dir | A - Grant | $0.00 | +374.0K | 374.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-11-24 | C | A | 723,440 | $0.00 | 746,507 | D | — | — | (F2) Includes 506,440 shares of common stock that vest over an approximately three year period, subject to the continuing service of the Reporting Person on each vesting date. (F3) Includes 522,588 shares of common stock that vest over an approximately three year period, subject to the continuing service of the Reporting Person on each vesting date. |
| 2 | Derivative | Series A Preferred Stock | 2023-11-24 | C | D | 18,086 | $0.00 | 0 | D | — · — to — | 723,440 Common Stock | (F1) Following stockholder approval of the conversion of Series A preferred stock into shares of common stock, each share of Series A preferred stock automatically converted on November 24, 2023 into 40 shares of common stock, subject to certain limitations. |
| 3 | Derivative | Stock Option (Right to Buy) | 2023-11-22 | A | A | 374,000 | $0.00 | 374,000 | D | $10.39 · — to 2033-11-22 | 374,000 Common Stock | (F4) This option represents a right to purchase 374,000 shares of the Issuer's common stock, one quarter of which will vest and become exercisable on November 22, 2024, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued employment with the Issuer at each vesting date. |